COVID-19 has challenged the global healthcare system through rapid proliferation and lack of existing treatment resulting in over 180 million cases and 3.8 million deaths since December 2019. Although pediatric patients only comprise 1%–2% of diagnosed cases, their incidence of acute kidney injury ranges from 8.2% to 18.2% compared to 49% in adults. Severe infection, initiated by dysregulated host response, can lead to multiorgan failure. In this review, we focus on the use of various blood filters approved for use in pediatric kidney replacement therapy to mitigate adverse effects of severe illness. Therapeutic effects of these blood filters range from cytokine removal (CytoSorb, HA330, HCO/MCO), endotoxin removal (Toraymyxin, CPFA), both cytokine and endotoxin removal (oXiris), and nonspecific removal of proteins (PMMA) that have already been established and can be used to mitigate the various effects of the cytokine storm syndrome in COVID-19.

Blood filters in children with COVID-19 and acute kidney injury: A review / R. Raina, S.K. Sethi, R. Chakraborty, S. Singh, S. Teo, A. Khooblall, G. Montini, T. Bunchman, R. Topaloglu, H.K. Yap. - In: THERAPEUTIC APHERESIS AND DIALYSIS. - ISSN 1744-9979. - (2022), pp. -1. [Epub ahead of print] [10.1111/1744-9987.13793]

Blood filters in children with COVID-19 and acute kidney injury: A review

G. Montini;
2022

Abstract

COVID-19 has challenged the global healthcare system through rapid proliferation and lack of existing treatment resulting in over 180 million cases and 3.8 million deaths since December 2019. Although pediatric patients only comprise 1%–2% of diagnosed cases, their incidence of acute kidney injury ranges from 8.2% to 18.2% compared to 49% in adults. Severe infection, initiated by dysregulated host response, can lead to multiorgan failure. In this review, we focus on the use of various blood filters approved for use in pediatric kidney replacement therapy to mitigate adverse effects of severe illness. Therapeutic effects of these blood filters range from cytokine removal (CytoSorb, HA330, HCO/MCO), endotoxin removal (Toraymyxin, CPFA), both cytokine and endotoxin removal (oXiris), and nonspecific removal of proteins (PMMA) that have already been established and can be used to mitigate the various effects of the cytokine storm syndrome in COVID-19.
blood filters; COVID-19; CVVHDF; CytoSorb; oXiris;
Settore MED/38 - Pediatria Generale e Specialistica
8-gen-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
Ther Apher Dial - 2022 - Raina - Blood filters in children with COVID‐19 and acute kidney injury A review.pdf

accesso riservato

Descrizione: Review article
Tipologia: Publisher's version/PDF
Dimensione 2.93 MB
Formato Adobe PDF
2.93 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/903910
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact